Sign in

CIK 0001672619 · Non-accelerated filer

Enliven Therapeutics, Inc.

Sign in to watch
Ticker
ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
811523849
Phone
650-547-5814
Business address
205 PARK ROAD, BURLINGAME, CA, 94010
Former names
IMARA Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$2,230,845
in 7 filings, $1.6M under 10b5-1 plans

Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Hohl Benjamin −$887K CHIEF FINANCIAL OFFICER sold 32% of stake
  2. Collins Helen Louise −$737K CHIEF MEDICAL OFFICER sold 38% of stake
  3. Garland J. Scott −$607K Director sold 100% of stake
Date Insider Transaction Shares Price Value Owned after
2020-03-16 Dalton Barbara Director Purchase +312,500 $16.00 $5.0M 1,557,722
2020-03-16 Dalton Barbara Director Conversion · Series Seed Preferred Stock −478,749 0
2020-03-16 Dalton Barbara Director Conversion · Series A Preferred Stock −5,470,492 0
2020-03-16 Dalton Barbara Director Conversion · Series B Preferred Stock −1,894,444 0
2020-03-16 Dalton Barbara Director Grant or award · Stock Option (right to buy) +15,457 15,457
2020-03-16 Bonita David P Director Conversion +1,594,902 2,532,402
2020-03-16 Bonita David P Director Conversion · Series B Preferred Stock −10,046,294 0
2020-03-16 Bonita David P Director Grant or award · Stock Option (right to buy) +15,457 15,457
2020-03-16 Agger Mette Kirstine Director Conversion +1,245,222 1,245,222
2020-03-16 Agger Mette Kirstine Director Purchase +187,500 $16.00 $3.0M 1,432,722
2020-03-16 Agger Mette Kirstine Director Conversion · Series Seed Preferred Stock −478,749 0
2020-03-16 Agger Mette Kirstine Director Conversion · Series A Preferred Stock −5,470,492 0
2020-03-16 Agger Mette Kirstine Director Conversion · Series B Preferred Stock −1,894,444 0
2020-03-16 Agger Mette Kirstine Director Grant or award · Stock Option (right to buy) +15,457 15,457
2020-03-16 Chin Mark Director Conversion +1,367,058 1,367,058
2020-03-16 Chin Mark Director Purchase +187,500 $16.00 $3.0M 1,554,558
2020-03-16 Chin Mark Director Conversion · Series B Preferred Stock −8,611,110 0
2020-03-16 Chin Mark Director Grant or award · Stock Option (right to buy) +15,457 15,457
2020-03-16 GOLDFISCHER CARL Director Conversion +690,232 690,232
2020-03-16 GOLDFISCHER CARL Director Conversion +13,148 703,380

Page 39 of 42 · 825 trades